XL092, BELZUTIFAN, XL092, XL092, Placebo to Zanzalintinib
MK-6482-034
Phase 3 small_molecule active
Quick answer
XL092, BELZUTIFAN, XL092, XL092, Placebo to Zanzalintinib for Renal Cell Carcinoma is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Renal Cell Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active